Type 2 Diabetes Marks a Distinct Clinical Pattern in Sjögren’s Disease
In a multicenter real-world analysis from the Italian Research Group on Sjögren’s Syndrome, type 2 diabetes mellitus separated patients with Sjögren’s disease into a clinically heavier metabolic subgroup with a different serologic profile. Among 245 patients, 100 carried a diagnosis of diabetes, and the diabetic group arrived with the expected cardiometabolic clustering: higher body mass index, more hypertension, more hypercholesterolemia, and more hypertriglyceridemia. The signal is clinically familiar at the bedside, but it carries special weight in Sjögren’s disease, where systemic autoimmunity and vascular risk often travel together rather than separately.
The cohort was older, predominantly female, and had a mean age of 70 years with a standard deviation of 12. Disease activity looked similar between groups, although ESSDAI data were available for only 54% of patients. That incomplete disease-activity capture matters because it leaves some uncertainty around whether the apparent similarity in inflammatory burden is fully reliable. Still, the available data do not support a simple story in which diabetes merely coexists with more active Sjögren’s disease; instead, the metabolic phenotype appears to sit beside a different immunologic profile.
Lower Anti-SSB/La and Low C3 Clustered With Diabetes
After adjustment for age and disease duration, diabetes was associated with lower odds of anti-SSB/La positivity and low C3. The odds ratio for anti-SSB/La positivity was 0.48, with a 95% confidence interval of 0.25 to 0.88. For low C3, the odds ratio was 0.30, with a 95% confidence interval of 0.10 to 0.76. Conditional analyses that accounted for the matched sets produced similar estimates, reinforcing the direction of effect across analytic approaches.
Those serologic differences are biologically interesting because anti-SSB/La and complement consumption are often linked to broader B-cell activation in Sjögren’s disease. A lower prevalence of these markers in the diabetic group may point to a subset in which metabolic disease is accompanied by a less overtly B-cell-driven serologic signature, or to a different inflammatory architecture altogether. The study does not prove mechanism, and it does not justify overreading causality. It does, however, make clear that diabetes in Sjögren’s disease is not a neutral comorbidity in the immunologic profile.
One sentence captures the practical implication: diabetes was not just more common in a heavier cardiometabolic subgroup, it also tracked with less frequent expression of two serologic findings often used to characterize autoimmune activity.
Cardiovascular History Was Driven by Age and Hypertension
The investigators also examined factors associated with a history of cardiovascular events. Thirty-one patients had such a history. In the primary Firth logistic model, fitted to 239 patients, age and hypertension emerged as the significant predictors. Each additional year of age was associated with higher odds of cardiovascular history, with an odds ratio of 1.07 and a 95% confidence interval of 1.02 to 1.12. Hypertension carried an odds ratio of 3.21, with a 95% confidence interval of 1.27 to 9.54. The p values were 0.005 for age and 0.012 for hypertension.
Anti-SSB/La, smoking, and current hydroxychloroquine use were not significantly associated with cardiovascular history in this model. Multiple-imputation analyses were consistent with the primary findings. The absence of a measurable association for hydroxychloroquine in this dataset should not be stretched into a broader therapeutic judgment; the study was observational, the cardiovascular endpoint was a history of events rather than prospectively adjudicated outcomes, and the analysis was exploratory.
Cardiovascular risk in Sjögren’s disease often reflects the same forces seen in general internal medicine: age, blood pressure, lipid burden, and metabolic disease. Here, hypertension stood out sharply. In a population already burdened by systemic autoimmunity and frequent metabolic comorbidity, blood pressure appears to remain the most actionable variable in the cardiovascular history signal.
Metformin Did Not Show a Clear Association in Adjusted Models
Adjusted metformin analyses did not show statistically significant associations. The absence of a signal should be interpreted cautiously because the study was not designed to establish treatment effects, and medication use in a retrospective cohort often reflects confounding by indication, treatment duration, and differences in diabetes severity. Even so, the lack of a detectable association means the dataset does not support a claim that metformin altered the serologic or cardiovascular patterns examined here.
The article’s strength lies in its real-world multicenter structure and its effort to account for age, disease duration, and the matched design in sensitivity analyses. The analytic approach was careful enough to avoid the most obvious pitfalls of retrospective comparison. Yet the findings still sit within the limits of observational inference, and the serologic associations were identified at nominal significance without correction for multiple testing. That leaves them informative, but provisional.
Why This Matters in Daily Rheumatology Care
For clinicians managing Sjögren’s disease, the study draws a sharper line between metabolic comorbidity and autoimmune phenotype than is often appreciated in routine visits. Patients with type 2 diabetes in this cohort were not only more likely to have obesity-related and lipid-related risk factors; they also showed lower prevalence of anti-SSB/La and low C3. In a disease where serology often guides phenotyping, prognostic framing, and referral patterns, that difference may influence how clinicians think about overlapping systemic risk.
The findings also reinforce a basic but easy-to-neglect message: cardiovascular history in Sjögren’s disease remains closely tied to age and hypertension. In practice, that means the blood pressure cuff may be more informative than any single autoantibody when estimating near-term vascular risk.
The study ends with an unresolved question rather than a conclusion. These associations need independent replication and prospective validation before they can be used to reshape risk stratification or mechanistic thinking in Sjögren’s disease with type 2 diabetes. Until then, the data support a cautious reading: diabetes identifies a metabolically heavier subgroup with a different serologic signature, while cardiovascular history in this cohort follows the familiar path of aging and hypertension.